MiNK Therapeutics logo
MiNK Therapeutics
INKT | NASDAQ
Chart Builder DCF Calculator
$9.35
+$0.01 (+0.11%)
At close: Nov 16, 2026, 4:00 PM ET
$9.26
-$0.09 (-0.96%)
After-hours: Nov 16, 2026, 7:30 PM ET

MiNK Therapeutics Company Profile

Company profile explained

Company Profile

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Key Executives

Name Position
Jennifer S. Buell Co-Founder, President, CEO & Director
Austin Charette Principal Accounting Officer
Garo H. Armen Executive Chairman
Marco Purbhoo Head of Translational Medicine
Melissa Orilall Principal Financial Officer
Terese C. Hammond Head of Inflammatory & Pulmonary Diseases

Latest SEC Filings

Date Type Title
Oct 14, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Aug 13, 2026 S-8 Filing
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
Jun 23, 2026 8-K Current Report
View All SEC Filings ➞
MiNK Therapeutics
MiNK Therapeutics logo
Country United States
IPO Date Oct 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Jennifer S. Buell

Contact Details

149 Fifth Avenue New York City, New York 10010 United States

Stock Details

Ticker Symbol INKT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001840229
CUSIP Number 603693201
ISIN Number US6036932019
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.